Axsome Therapeutics, Inc.

Fundamentals6.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • Very high gross-margin
  • Large operating losses
  • Elevated leverage

AI
AI Summary

6.0

Axsome has transitioned into a commercial-growth company where Auvelity meaningfully de-risks near-term revenue but the investment thesis now hinges on execution to tighten rising gross-to-net (GTN) discounts and align SG&A so quarterly free-cash-flow turns positive; failure to improve GTN or curb spending amid ~2.4x leverage will likely force dilutive financing and trigger material downside. Monitor GTN rate, quarterly FCF trajectory, and cash/debt runway as the decisive short-term catalysts for upside vs. downside.

CommercialScale
GTNRisk
CashFlow‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Very high gross-margin
  • Large operating losses
  • Elevated leverage

AXSM has industry-leading gross margins and a multi-quarter cash runway but is burning cash with large R&D/SG&A-driven operating losses, high leverage versus equity, negative free cash flow, and a market valuation that far exceeds fundamentals.

StrongGross
CashBurn

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below SMA
  • Near support
  • High volatility

Stock is in a clear near-term downtrend over the last month, trading below its last-month SMA and sitting nearer support (~$154–158) with resistance around $163–169, so a break below $154 would raise downside risk while a sustained move above $163–166 would be needed to signal a reversal.

bearish
watch
Support Level: $154.12 and $156–158
Resistance Level: $163–166 (near-term), cluster $166–169 (secondary), high $183.72

Mid-teens percent peak-to-trough swing over the last month indicating elevated short-term volatility

Sentiment & News

7.0

Key News Insights:

  • Auvelity-driven growth
  • Wider-than-expected loss
  • Insider & institutional activity

Axsome's 2025 revenue jumped 66% to $638.5M driven by Auvelity sales, attracting investor and insider activity but still facing widened losses and analyst concerns over valuation and long‑term pipeline risk.

commercial
valuation

Strong commercial traction boosts upside potential, but profitability shortfalls and valuation scrutiny will likely keep share volatility and analyst caution in the near term